이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension

2026년 9월 9일 업데이트: Guo-Qing Jiang, Northern Jiangsu People's Hospital

Effect of Laparoscopy Splenectomy and Azygoportal Disconnectionon Renal Function in Cirrhotic Patients With Portal Hypertension

Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to the kidneys and fluid buildup in the abdomen (ascites). Laparoscopy splenectomy and azygoportal disconnection (LSD) is a minimally invasive surgery commonly used to treat bleeding from swollen veins in these patients, but its impact on kidney function recovery remains unclear.

This study will review medical records of patients with liver cirrhosis and portal hypertension who underwent LSD at our hospital. We will measure kidney function using estimated glomerular filtration rate (eGFR) before surgery and at 3, 6, 9, and 12 months after surgery to evaluate changes over time. We will also examine whether factors such as fluid buildup in the abdomen (ascites) before surgery are associated with kidney function changes after LSD.

The goal is to better understand how LSD affects kidney function in these patients and to identify factors that may predict kidney function recovery, which could help improve care for cirrhotic patients undergoing this surgery.

연구 개요

상세 설명

Liver cirrhosis is associated with systemic hemodynamic disturbances, reduced effective circulating volume, and renal hypoperfusion, creating a high risk of renal dysfunction and hepatorenal syndrome (HRS)-a life-threatening condition reflecting the critical hepatorenal interaction. Patients with cirrhosis and portal hypertension frequently have subclinical or overt renal impairment preoperatively. Laparoscopy splenectomy and azygoportal disconnection (LSD) is a standard intervention for cirrhotic patients with portal hypertension, but its impact on long-term renal function recovery remains unclear.

This single-center retrospective cohort study will be conducted at the Department of Hepatobiliary Surgery, Subei People's Hospital Affiliated to Yangzhou University, Yangzhou, China. We will retrospectively collect clinical and follow-up data from patients with liver cirrhosis and portal hypertension who underwent LSD between February 2012 and February 2025.

Patients will be stratified into two groups based on preoperative estimated glomerular filtration rate (eGFR): impaired renal function group (<90 mL/min/1.73m²) and normal renal function group (≥90 mL/min/1.73m²). Kidney function will be assessed using eGFR calculated with the 2021 CKD-EPI creatinine equation at five time points: preoperative baseline and postoperative months 3, 6, 9, and 12.

Statistical analyses will include linear mixed-effects models (LMM) to evaluate eGFR change trajectories and group differences over time; multivariable linear regression to identify factors independently associated with eGFR change (ΔeGFR = postoperative month 12 eGFR - preoperative eGFR); and multivariable logistic regression (limited to patients with baseline eGFR <90 mL/min/1.73m²) to identify predictors of renal function recovery to normal (eGFR ≥90 mL/min/1.73m²).

The study aims to evaluate whether LSD is associated with kidney function improvement in patients with liver cirrhosis and portal hypertension, whether the degree of improvement differs between patients with and without pre-existing renal impairment, and whether preoperative factors such as ascites severity are associated with the magnitude of renal function recovery. These findings may help fill an important gap in understanding the hepatorenal axis after LSD and guide perioperative renal protection strategies in this high-risk population.

연구 유형

관찰

등록 (실제)

496

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

해당 없음

샘플링 방법

비확률 샘플

연구 인구

This is a retrospective, single-center, observational cohort study. The study population consists of adult patients with liver cirrhosis, splenomegaly and hypersplenism, and portal hypertension bleeding who underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at the Department of Hepatobiliary Surgery, Subei People's Hospital Affiliated to Yangzhou University between February 2012 and February 2025. Patients were identified from electronic medical records and followed for up to 12 months postoperatively to assess renal function dynamics. The study aimed to evaluate the effect of LSD on renal function recovery and identify factors associated with postoperative renal outcomes in this high-risk population.

설명

Inclusion Criteria:

  1. Age ≥18 years.
  2. Diagnosis of liver cirrhosis with portal hypertension.
  3. Underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at our institution.
  4. Adequate preoperative and postoperative clinical and follow-up data for analysis.
  5. Preoperative and postoperative eGFR data available at the specified time points (baseline, month 3, 6, 9, and 12).

Exclusion Criteria:

  1. Child-Pugh Class C liver cirrhosis.
  2. Primary renal diseases (e.g., glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.).
  3. Previous abdominal surgery that precluded safe laparoscopic splenectomy and azygoportal disconnection (LSD).
  4. Severe cardiac, pulmonary, or cerebrovascular dysfunction; malignant tumors; or primary hematological disorders.
  5. Hepatic encephalopathy or refractory ascites within 1 month before surgery.
  6. Pregnancy or lactation.
  7. Poor compliance or inability to complete follow-up.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
LSD-treated Patients with Liver Cirrhosis and Portal Hypertension
Patients who underwent laparoscopy splenectomy and azygoportal disconnection for liver cirrhosis with portal hypertension
A minimally invasive surgical procedure involving laparoscopic removal of the spleen and ligation of perigastric and esophageal varices to reduce portal hypertension and prevent variceal bleeding.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Serum Creatinine (Scr) Level
기간: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Change in serum creatinine (Scr) level, used for eGFR calculation.
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Estimated Glomerular Filtration Rate (eGFR)
기간: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Change in estimated glomerular filtration rate (eGFR) calculated using the 2021 CKD-EPI creatinine equation. eGFR was assessed at preoperative baseline and postoperative months 3, 6, 9, and 12 to evaluate longitudinal renal function changes.
At preoperative baseline, postoperative month 3, month 6, month 9, month 12

2차 결과 측정

결과 측정
측정값 설명
기간
Blood Urea Nitrogen (BUN) Level
기간: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Changes in BUN level as additional indicators of renal function.
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Blood Uric Acid (UA) Level
기간: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Changes in UA level as additional indicators of renal function.
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Postoperative Complications
기간: At postoperative day 1, day 3, day 7, month 1, month 3, month 6, month 12
Postoperative complications including bleeding, infection, hepatic encephalopathy, and ascites.
At postoperative day 1, day 3, day 7, month 1, month 3, month 6, month 12
Albumin
기간: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Changes in serum albumin levels.
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Total Bilirubin Level
기간: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
Changes in serum total bilirubin levels.
At preoperative baseline, postoperative month 3, month 6, month 9, month 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 의자: guoqing jiang, Clinical Medical College, Yangzhou University

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2012년 2월 1일

기본 완료 (실제)

2026년 2월 1일

연구 완료 (실제)

2026년 8월 1일

연구 등록 날짜

최초 제출

2026년 8월 11일

QC 기준을 충족하는 최초 제출

2026년 9월 9일

처음 게시됨 (실제)

2026년 9월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 9일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다